AtriCure (ATRC) Tops Q1 EPS by 5c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus

Go back to AtriCure (ATRC) Tops Q1 EPS by 5c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus

AtriCure Inc. (ATRC) PT Raised to $81 at Needham & Company

April 28, 2021 6:20 AM EDT

Needham & Company analyst Mike Matson raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $81.00 (from $74.00) while maintaining a Buy rating.

The analyst commented, "ATRC's 1Q21 revenue, adjusted EBITDA, and adjusted EPS all beat consensus. The impact from the pandemic eased during the... More